Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

America is increasingly reliant on data coming from other countries or from drug companies about the coronavirus vaccines' effectiveness over time, particularly when it comes to the Delta variant.

Between the lines: Top Biden officials are growing frustrated with the lack of internal visibility into data being collected by the CDC, particularly as they try to deal with Delta's spread.

Driving the news: Friday saw an international coronavirus vaccine data dump.

  • A South African study found that Johnson & Johnson's vaccine is effective against the Delta variant, particularly against death, Reuters reports.
  • Public Health England published data collected through the end of July showing that vaccinated people are less likely than the unvaccinated to become infected with Delta, but once infected, they may be equally contagious.
  • Earlier last week, Imperial College London released a study that found vaccine's effectiveness against symptomatic disease had dropped significantly with the rise of Delta in the U.K.

Meanwhile, the CDC also published data on the vaccines' effectiveness in older Americans — except the data only went through April, before Delta became dominant in the U.S.

  • It also published two other smaller studies on vaccine effectiveness that included data through June, but they took place in specific geographic locations.
  • CDC Director Rochelle Walensky said last week that the agency is "actively working" to update its data "in the context of the Delta variant."

What they're saying: The cohort data, which follows the vaccines' effectiveness in specific groups — like older Americans — over time, is what would be really useful to see.

  • But the CDC's culture is to only release data once it's ready for publication. That may make sense for the public, but it's frustrating for policymakers trying to make real-time decisions, said one source familiar with internal discussions.
  • "That's where the tension is, like 'Where the hell are the data?'" the source said.

The other side: "Countries with centralized health care systems have advantages here. The USA doesn’t work like that," said Cornell virologist John Moore.

  • "This is an old, old problem, nothing to do with today’s CDC," he added.

The big picture: The Biden administration is ultimately trying to figure out how well-protected different demographics are against the virus, and for how long. From there, they can decide who should get booster shots.

  • But while the administration waits for more information, telling the public only that boosters aren't necessary right now, drug companies and other countries are filling the data and communication void.
  • "Just think we live in a country which is incapable of telling us the percent vaccinated or unvaccinated who require hospitalization for covid. No less any more data about them. Or track breakthrough infections. Thanks @CDCgov," tweeted Eric Topol, executive vice president of Scripps Research.

Go deeper

Tina Reed, author of Vitals
Oct 26, 2021 - Health

FDA panel endorses Pfizer vaccines for 5-to-11-year-olds

Photo: Justin Sullivan/Getty Images

Members of the Food and Drug Administration's vaccine expert panel Tuesday endorsed a two-dose series of Pfizer-BioNTech's COVID-19 vaccine for children ages 5–11. The final vote was 17 members in favor, with one member abstaining.

Why it matters: While not binding, the decision is a long-awaited step toward getting COVID vaccines in the arms of some of the youngest Americans potentially in time to get many fully vaccinated in advance of the holiday season.

Updated 38 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: CDC says some immunocompromised people can get fourth COVID shot — FDA panel endorses Pfizer vaccines for 5-11 year olds — Moderna says vaccine shows strong immune response in kids
  2. Health: COVID cases, deaths at meat plants were far higher than previously thought — 96% of Tyson Foods employees vaccinated ahead of mandate deadline — U.S. releases updated vaccination, testing rules for foreign travelers
  3. Politics: Louisiana lifts mask mandate except for some schools — Alabama governor orders state agencies to fight federal vaccine mandate — Axios-Ipsos poll: Confidence in Biden COVID recovery tumbles
  4. Education: Benefits of vaccine for children outweigh risks, FDA says — Education secretary reveals limits to Biden’s mask push on states — LA extends deadline for school employee vaccinations.
  5. Variant tracker: Where different strains are spreading.
23 hours ago - Health

Louisiana lifts mask mandate except for some schools

Louisiana Gov. John Bel Edwards. Photor: Al Drago/Bloomberg via Getty Images

Louisiana's statewide mask mandate is lifting for all settings except for some schools starting on Wednesday, Gov. John Bel Edwards (D) announced.

The big picture: The requirement has been in place since early August as the Delta variant surged across the state. Edwards tweeted Tuesday there had been a "sustained improvement across the state in new cases, test positivity & hospitalizations."